Joaquim Bellmunt explains a bit about why the trial examining adjuvant atezolizumab in urothelial cancer was not successful and what it means for the field.
Joaquim Bellmunt explains a bit about why the trial examining adjuvant atezolizumab in urothelial cancer was not successful and what it means for the field.